

---

## ERRATUM

---

The April 1, 2015 article by Klotz et al, entitled, “Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT,” (J Clin Oncol 33:1151-1156, 2015) was published with an error.

There was a discrepancy in the quoted *P* values between the text and Table 2.

In the Results section, third paragraph, the first sentence was given as: “There was a significant difference among the three testosterone groups in time to CRPC (*P* = .024; Figs 2A to 2C).” However, it should have been given as “There was a significant difference among the three testosterone groups in time to CRPC (*P* = **.015; Table 2**; Figs 2A to 2C).

Also in the third paragraph of the Results section, the third sentence was given as:

“Similarly, those patients with a median testosterone level > 0.7 nmol/L had a higher risk of developing CRPC (*P* = .01;..).” However, it should have been, “Similarly, those patients with a median testosterone level > 0.7 nmol/L had a higher risk of developing CRPC (*P* = **.02;..**).”

In the Results section, fourth paragraph, the first sentence was given as: “CSS was significantly different among the three groups (*P* = .015).” However, it should have been “CSS was significantly different among the three groups (*P* = **.02**).”

In Table 2, under the median (time to death resulting from prostate cancer), the last two numbers of “8.93” and “10.00” should have been “**NR**”, “**NR**” instead.

This has been corrected as of May 5, 2016. The authors apologize for the mistake.

DOI: 10.1200/JCO.2016.68.1882; published June 1, 2016

---